INSERT INTO kol_info VALUES 
	('Philip G Conaghan', 'rheumatoid_arthritis', 'Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; NIHR Leeds Biomedical Research Centre, Leeds, UK. Electronic address: p.conaghan@leeds.ac.uk.', 150.4, 18, 78, 11.0), 
	('Edward Keystone', 'rheumatoid_arthritis', 'University of Toronto, Toronto, Ontario, Canada.', 175.0, 11, 67, 11.0), 
	('Hideto Kameda', 'rheumatoid_arthritis', 'Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan.', 274.6, 14, 62, 11.0), 
	('Cristiano A F Zerbini', 'rheumatoid_arthritis', NULL, 291.0, 12, 67, 11.0), 
	('Howard Amital', 'rheumatoid_arthritis', 'Department of Medicine 'B' and Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.', 356.8, 6, 37, 11.0), 
	('Ronald van Vollenhoven', 'rheumatoid_arthritis', 'Amsterdam University Medical Centres, Amsterdam, The Netherlands.', 420.2, 12, 67, 11.0), 
	('Robert Landewé', 'rheumatoid_arthritis', 'Academic Medical Center, Amsterdam, The Netherlands.', 454.8, 10, 51, 11.0), 
	('Stephen Hall', 'rheumatoid_arthritis', NULL, 482.20000000000005, 10, 63, 9.0), 
	('Kunihiro Yamaoka', 'rheumatoid_arthritis', 'Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan.', 489.8, 12, 47, 11.0), 
	('Eun Bong Lee', 'rheumatoid_arthritis', 'Seoul National University, Seoul, Korea.', 521.6, 16, 72, 11.0), 
	('Annelies Boonen', 'rheumatoid_arthritis', 'Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands.', 527.0, 7, 39, 10.0), 
	('Karel Pavelka', 'rheumatoid_arthritis', 'Institute of Rheumatology.', 527.6, 11, 68, 10.0), 
	('Peter Junker', 'rheumatoid_arthritis', 'Faculty of Health Sciences, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, J.B. Winsløws Vej 4, Indgang 96, 1. Sal, 5000, Odense, Denmark.', 551.0, 10, 38, 11.0), 
	('Kristian Stengaard-Pedersen', 'rheumatoid_arthritis', 'Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.', 573.4, 14, 50, 11.0), 
	('Ricardo M Xavier', 'rheumatoid_arthritis', 'Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.', 588.4, 7, 34, 10.0), 
	('Stefan Florentinus', 'rheumatoid_arthritis', NULL, 598.4, 9, 36, 11.0), 
	('Vivian P Bykerk', 'rheumatoid_arthritis', 'Weill Cornell Medical College, New York, New York.', 613.0, 10, 49, 10.0), 
	('Benjamin Hsu', 'rheumatoid_arthritis', 'Immunology Development, Janssen Research and Development LLC, Spring House, Pennsylvania, USA.', 616.4, 12, 49, 11.0), 
	('Georg Schett', 'rheumatoid_arthritis', 'Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nurnberg and Universitatsklinikum Erlangen, Erlangen, Germany.', 616.6, 5, 32, 11.0), 
	('Atsushi Kawakami', 'rheumatoid_arthritis', 'Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences.', 631.0, 8, 44, 10.0), 
	('Daniel E Furst', 'rheumatoid_arthritis', 'Department of Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA.', 641.8, 19, 92, 10.0), 
	('Alain Cantagrel', 'rheumatoid_arthritis', 'Rheumatology Department, University Paul Sabatier Toulouse III, Purpan Hospital, 31059, Toulouse, France.', 642.4, 8, 39, 10.0), 
	('Koichi Amano', 'rheumatoid_arthritis', 'Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.', 643.4, 13, 43, 11.0), 
	('Vibeke Strand', 'rheumatoid_arthritis', 'Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA.', 686.8, 32, 155, 11.0), 
	('Jiri Vencovsky', 'rheumatoid_arthritis', 'Institute of Rheumatology, Charles University, Prague, Czech Republic.', 713.0, 6, 39, 10.0), 
	('Ernest Choy', 'rheumatoid_arthritis', 'Section of Rheumatology, Division of Infection and Immunity, Cardiff University, Cardiff, UK.', 724.6, 6, 35, 10.0), 
	('Daniel Aletaha', 'rheumatoid_arthritis', 'Division of Rheumatology, Medical University of Vienna, Wien, Austria daniel.aletaha@meduniwien.ac.at.', 727.0, 13, 62, 9.0), 
	('Benjamin A Fisher', 'rheumatoid_arthritis', 'Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.', 730.6, 6, 34, 11.0), 
	('Jeffrey Kaine', 'rheumatoid_arthritis', 'Independent Healthcare Associates Inc, Cullowhee, NC, USA.', 735.4, 4, 27, 11.0), 
	('Michael T Nurmohamed', 'rheumatoid_arthritis', 'Amsterdam Rheumatology and Immunology Center, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, The Netherlands.', 748.6, 12, 69, 10.0), 
	('Patrick Durez', 'rheumatoid_arthritis', 'Rheumatology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium.', 752.4000000000001, 19, 105, 10.0), 
	('Iain B McInnes', 'rheumatoid_arthritis', 'Glasgow Biomedical Research Centre, Glasgow, UK.', 767.4, 14, 73, 11.0), 
	('David Gruben', 'rheumatoid_arthritis', 'Pfizer Inc, Groton, Connecticut.', 771.0, 9, 41, 9.0), 
	('Dirkjan van Schaardenburg', 'rheumatoid_arthritis', 'Amsterdam Rheumatology and Immunology Center, Department of Rheumatology, Reade, Amsterdam.', 772.8, 11, 54, 12.0), 
	('Charles Peterfy', 'rheumatoid_arthritis', 'Spire Sciences, Inc., Boca Raton, FL, USA.', 774.0, 11, 66, 11.0), 
	('Eric L Matteson', 'rheumatoid_arthritis', 'Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA. matteson.eric@mayo.edu.', 777.4, 8, 38, 11.0), 
	('Pit J S M Kerstens', 'rheumatoid_arthritis', 'Reade, Amsterdam, The Netherlands.', 784.0, 6, 31, 10.0), 
	('Naoki Ishiguro', 'rheumatoid_arthritis', 'Nagoya University, Aichi, Japan.', 787.4, 24, 47, 11.0), 
	('Jacob M van Laar', 'rheumatoid_arthritis', 'Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands.', 800.6, 11, 43, 10.0), 
	('Elizabeth C Hsia', 'rheumatoid_arthritis', 'Janssen Research & Development, LLC, Spring House, PA, USA.', 811.0, 6, 31, 11.0), 
	('Rieke Alten', 'rheumatoid_arthritis', 'University Medicine Berlin, Berlin, Germany.', 815.0, 20, 97, 10.0), 
	('Hartmut Kupper', 'rheumatoid_arthritis', 'Department of Immunology Development, AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany.', 817.6, 6, 32, 11.0), 
	('Johannes W G Jacobs', 'rheumatoid_arthritis', NULL, 821.0, 17, 50, 10.0), 
	('Jonathan Kay', 'rheumatoid_arthritis', 'University of Massachusetts Medical School and UMass Memorial Medical, Worcester, MA, USA.', 830.2, 8, 46, 11.0), 
	('Su Chen', 'rheumatoid_arthritis', 'AbbVie Inc., North Chicago, Illinois.', 835.0, 7, 33, 9.0), 
	('Adeline Ruyssen-Witrand', 'rheumatoid_arthritis', 'UMR 1027 INSERM, Paul Sabatier University, Toulouse.', 842.6, 8, 37, 10.0), 
	('Maarten Boers', 'rheumatoid_arthritis', 'Department of Epidemiology and Biostatistics.', 862.6, 25, 103, 12.0), 
	('Laure Gossec', 'rheumatoid_arthritis', 'AP-HP, Pitié Salpêtrière Hospital.', 873.2, 17, 70, 10.0), 
	('Samuel H Zwillich', 'rheumatoid_arthritis', 'Pfizer Inc, Groton, Connecticut.', 878.2, 9, 34, 9.0), 
	('Joshua F Baker', 'rheumatoid_arthritis', 'Philadelphia Veteran's Administration Medical Center and the University of Pennsylvania, Philadelphia, PA, USA.', 881.2, 8, 22, 11.0);

INSERT INTO kol_pub_list VALUES 
	('Philip G Conaghan', 'Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept.'), 
	('Philip G Conaghan', 'Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis.'), 
	('Philip G Conaghan', 'Relationship of patient-reported outcomes with MRI measures in rheumatoid arthritis.'), 
	('Philip G Conaghan', 'Determining MRI Inflammation Targets When Considering a Rheumatoid Arthritis Treat-to-Target Strategy: Results of a Randomized, Placebo-Controlled Trial.'), 
	('Philip G Conaghan', 'The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy.'), 
	('Philip G Conaghan', 'Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.'), 
	('Philip G Conaghan', 'T-cell subset abnormalities predict progression along the Inflammatory Arthritis disease continuum: implications for management.'), 
	('Philip G Conaghan', 'Greater body mass independently predicts less radiographic progression on X-ray and MRI over 1-2 years.'), 
	('Philip G Conaghan', 'Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial.'), 
	('Philip G Conaghan', 'Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.'), 
	('Philip G Conaghan', 'Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.'), 
	('Philip G Conaghan', 'Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis.'), 
	('Philip G Conaghan', 'Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study.'), 
	('Philip G Conaghan', 'Genetic associations with radiological damage in rheumatoid arthritis: Meta-analysis of seven genome-wide association studies of 2,775 cases.'), 
	('Philip G Conaghan', 'Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis.'), 
	('Philip G Conaghan', 'Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study.'), 
	('Philip G Conaghan', 'Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study.'), 
	('Philip G Conaghan', 'Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Im<i>P</i>act of <i>R</i>esidual Inflammation Detected via Imaging T<i>E</i>chniques, <i>D</i>rug Levels and Patient Characteristics on the Outcome of Dose Taper<i>I</i>ng of Adalimumab in <i>C</i>linical Remission Rheumatoid Ar<i>T</i>hritis (<i>RA</i>) patients (PREDICTRA).'), 
	('Edward Keystone', 'Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.'), 
	('Edward Keystone', 'Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6.'), 
	('Edward Keystone', 'Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab.'), 
	('Edward Keystone', 'Identification of Distinct Disease Activity Trajectories in Methotrexate-Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty-Four Months.'), 
	('Edward Keystone', 'Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis.'), 
	('Edward Keystone', 'Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: a post-hoc analysis of a randomized phase III trial.'), 
	('Edward Keystone', 'RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studies.'), 
	('Edward Keystone', 'Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis.'), 
	('Edward Keystone', 'A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.'), 
	('Edward Keystone', 'Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.'), 
	('Edward Keystone', 'Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.'), 
	('Hideto Kameda', 'Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study.'), 
	('Hideto Kameda', 'Haemoglobin changes and disease activity in Japanese patients with rheumatoid arthritis treated with sarilumab.'), 
	('Hideto Kameda', 'A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis.'), 
	('Hideto Kameda', 'Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trials.'), 
	('Hideto Kameda', 'Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54.'), 
	('Hideto Kameda', 'Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE).'), 
	('Hideto Kameda', 'Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.'), 
	('Hideto Kameda', 'Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.'), 
	('Hideto Kameda', 'Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study.'), 
	('Hideto Kameda', 'Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.'), 
	('Hideto Kameda', 'Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial.'), 
	('Hideto Kameda', 'A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.'), 
	('Hideto Kameda', 'Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA).'), 
	('Hideto Kameda', 'Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial.'), 
	('Cristiano A F Zerbini', 'Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.'), 
	('Cristiano A F Zerbini', 'Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.'), 
	('Cristiano A F Zerbini', 'Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial.'), 
	('Cristiano A F Zerbini', 'Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.'), 
	('Cristiano A F Zerbini', 'Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.'), 
	('Cristiano A F Zerbini', 'Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab.'), 
	('Cristiano A F Zerbini', 'Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.'), 
	('Cristiano A F Zerbini', 'Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomes.'), 
	('Cristiano A F Zerbini', 'Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.'), 
	('Cristiano A F Zerbini', 'Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.'), 
	('Cristiano A F Zerbini', 'Maintenance of low disease activity and remission with etanercept-disease-modifying antirheumatic drug (DMARD) combination therapy compared with treatment with DMARDs alone in Latin American patients with active rheumatoid arthritis: Subset analysis of a randomized trial.'), 
	('Cristiano A F Zerbini', 'Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.'), 
	('Howard Amital', 'Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.'), 
	('Howard Amital', 'Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study.'), 
	('Howard Amital', 'Effect of Tocilizumab on Fatigue and Bone Mineral Density in Patients with Rheumatoid Arthritis.'), 
	('Howard Amital', 'Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab.'), 
	('Howard Amital', 'Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.'), 
	('Howard Amital', 'Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.'), 
	('Ronald van Vollenhoven', 'The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials.'), 
	('Ronald van Vollenhoven', 'A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.'), 
	('Ronald van Vollenhoven', 'Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.'), 
	('Ronald van Vollenhoven', 'Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis.'), 
	('Ronald van Vollenhoven', 'Identification of Distinct Disease Activity Trajectories in Methotrexate-Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty-Four Months.'), 
	('Ronald van Vollenhoven', 'Pain Over Two Years After Start of Biologic Versus Conventional Combination Treatment in Early Rheumatoid Arthritis: Results From a Swedish Randomized Controlled Trial.'), 
	('Ronald van Vollenhoven', 'Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial.'), 
	('Ronald van Vollenhoven', 'Blood PD-1+TFh and CTLA-4+CD4+ T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis.'), 
	('Ronald van Vollenhoven', 'Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).'), 
	('Ronald van Vollenhoven', 'Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study.'), 
	('Ronald van Vollenhoven', 'Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.'), 
	('Ronald van Vollenhoven', 'Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.'), 
	('Robert Landewé', 'Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis.'), 
	('Robert Landewé', 'Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritis.'), 
	('Robert Landewé', 'Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis.'), 
	('Robert Landewé', 'A psychometric analysis of outcome measures in peripheral spondyloarthritis.'), 
	('Robert Landewé', 'Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.'), 
	('Robert Landewé', 'Intra-articular etanercept treatment in inflammatory arthritis: A randomized double-blind placebo-controlled proof of mechanism clinical trial validating TNF as a potential therapeutic target for local treatment.'), 
	('Robert Landewé', 'Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.'), 
	('Robert Landewé', 'Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study.'), 
	('Robert Landewé', 'Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.'), 
	('Robert Landewé', 'Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.'), 
	('Stephen Hall', 'Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.'), 
	('Stephen Hall', 'Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.'), 
	('Stephen Hall', 'Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials.'), 
	('Stephen Hall', 'Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.'), 
	('Stephen Hall', 'Tofacitinib versus methotrexate in rheumatoid arthritis.'), 
	('Stephen Hall', 'Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).'), 
	('Stephen Hall', 'Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial.'), 
	('Stephen Hall', 'Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.'), 
	('Stephen Hall', 'Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.'), 
	('Stephen Hall', 'Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.'), 
	('Kunihiro Yamaoka', 'Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.'), 
	('Kunihiro Yamaoka', 'Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.'), 
	('Kunihiro Yamaoka', 'Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).'), 
	('Kunihiro Yamaoka', 'Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3).'), 
	('Kunihiro Yamaoka', 'Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE).'), 
	('Kunihiro Yamaoka', 'Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).'), 
	('Kunihiro Yamaoka', 'Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).'), 
	('Kunihiro Yamaoka', 'Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events.'), 
	('Kunihiro Yamaoka', 'Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study.'), 
	('Kunihiro Yamaoka', 'Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.'), 
	('Kunihiro Yamaoka', 'Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results.'), 
	('Kunihiro Yamaoka', 'Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.'), 
	('Eun Bong Lee', 'Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6.'), 
	('Eun Bong Lee', 'Effect of short-term methotrexate discontinuation on rheumatoid arthritis disease activity: post-hoc analysis of two randomized trials.'), 
	('Eun Bong Lee', 'Interaction between B-cell activation factor and methotrexate impacts immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis.'), 
	('Eun Bong Lee', 'Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.'), 
	('Eun Bong Lee', 'Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.'), 
	('Eun Bong Lee', 'Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study.'), 
	('Eun Bong Lee', 'Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials.'), 
	('Eun Bong Lee', 'Identification of Distinct Disease Activity Trajectories in Methotrexate-Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty-Four Months.'), 
	('Eun Bong Lee', 'Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis.'), 
	('Eun Bong Lee', 'Tofacitinib versus methotrexate in rheumatoid arthritis.'), 
	('Eun Bong Lee', 'Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study.'), 
	('Eun Bong Lee', 'The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.'), 
	('Eun Bong Lee', 'Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.'), 
	('Eun Bong Lee', 'Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.'), 
	('Eun Bong Lee', 'Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.'), 
	('Eun Bong Lee', 'Effect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjögren's Syndrome: a Double-Blind Randomized Control Study.'), 
	('Annelies Boonen', 'Prevalence of frailty and pre-frailty in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.'), 
	('Annelies Boonen', 'Short-term glucocorticoids reduce risk of chronic NSAID and analgesic use in early methotrexate-treated rheumatoid arthritis patients with favourable prognosis: subanalysis of the CareRA randomised controlled trial.'), 
	('Annelies Boonen', 'Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial.'), 
	('Annelies Boonen', 'Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: a randomised study.'), 
	('Annelies Boonen', 'An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open-Label Trial.'), 
	('Annelies Boonen', 'Content validity of global measures for at-work productivity in patients with rheumatic diseases: an international qualitative study.'), 
	('Annelies Boonen', 'Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.'), 
	('Karel Pavelka', 'Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response.'), 
	('Karel Pavelka', 'MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study.'), 
	('Karel Pavelka', 'Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.'), 
	('Karel Pavelka', 'S100A11 (calgizzarin) is released via NETosis in rheumatoid arthritis (RA) and stimulates IL-6 and TNF secretion by neutrophils.'), 
	('Karel Pavelka', 'Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.'), 
	('Karel Pavelka', 'Torque Teno Virus quantification for monitoring of immunomodulation with biologic compounds in the treatment of rheumatoid arthritis.'), 
	('Karel Pavelka', 'Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.'), 
	('Karel Pavelka', 'A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate.'), 
	('Karel Pavelka', 'Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab.'), 
	('Karel Pavelka', 'Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.'), 
	('Karel Pavelka', 'An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.'), 
	('Peter Junker', 'CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic 'window of opportunity'.'), 
	('Peter Junker', 'Type IV collagen metabolism is associated with disease activity, radiographic progression and response to tocilizumab in rheumatoid arthritis.'), 
	('Peter Junker', 'Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs.'), 
	('Peter Junker', 'Magnetic resonance imaging assessed inflammation in the wrist is associated with patient-reported physical impairment, global assessment of disease activity and pain in early rheumatoid arthritis: longitudinal results from two randomised controlled trials.'), 
	('Peter Junker', 'The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression.'), 
	('Peter Junker', 'A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial.'), 
	('Peter Junker', 'Soluble CD206 plasma levels in rheumatoid arthritis reflect decrease in disease activity.'), 
	('Peter Junker', 'The D-vitamin metabolite 1,25(OH)<sub>2</sub> D in serum is associated with disease activity and Anti-Citrullinated Protein Antibodies in active and treatment naïve, early Rheumatoid Arthritis Patients.'), 
	('Peter Junker', 'Similar lipid level changes in early rheumatoid arthritis patients following 1-year treat-to-target strategy with adalimumab plus methotrexate versus placebo plus methotrexate: secondary analyses from the randomised controlled OPERA trial.'), 
	('Peter Junker', 'Expression of soluble CD83 in plasma from early-stage rheumatoid arthritis patients is not modified by anti-TNF-α therapy.'), 
	('Kristian Stengaard-Pedersen', 'Methotrexate pharmacokinetic is influenced by co-administration of cyclosporin in rheumatoid arthritis patients. Results from a randomized clinical trial.'), 
	('Kristian Stengaard-Pedersen', 'CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic 'window of opportunity'.'), 
	('Kristian Stengaard-Pedersen', 'Tele-Health Followup Strategy for Tight Control of Disease Activity in Rheumatoid Arthritis: Results of a Randomized Controlled Trial.'), 
	('Kristian Stengaard-Pedersen', 'Macrophage activity assessed by soluble CD163 in early rheumatoid arthritis: association with disease activity but different response patterns to synthetic and biologic DMARDs.'), 
	('Kristian Stengaard-Pedersen', 'Magnetic resonance imaging assessed inflammation in the wrist is associated with patient-reported physical impairment, global assessment of disease activity and pain in early rheumatoid arthritis: longitudinal results from two randomised controlled trials.'), 
	('Kristian Stengaard-Pedersen', 'The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression.'), 
	('Kristian Stengaard-Pedersen', 'A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial.'), 
	('Kristian Stengaard-Pedersen', 'A disintegrin and metalloprotease-17 and galectin-9 are important regulators of local 4-1BB activity and disease outcome in rheumatoid arthritis.'), 
	('Kristian Stengaard-Pedersen', 'Soluble CD206 plasma levels in rheumatoid arthritis reflect decrease in disease activity.'), 
	('Kristian Stengaard-Pedersen', 'Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial.'), 
	('Kristian Stengaard-Pedersen', 'Changes in Soluble CD18 in Murine Autoimmune Arthritis and Rheumatoid Arthritis Reflect Disease Establishment and Treatment Response.'), 
	('Kristian Stengaard-Pedersen', 'The D-vitamin metabolite 1,25(OH)<sub>2</sub> D in serum is associated with disease activity and Anti-Citrullinated Protein Antibodies in active and treatment naïve, early Rheumatoid Arthritis Patients.'), 
	('Kristian Stengaard-Pedersen', 'Similar lipid level changes in early rheumatoid arthritis patients following 1-year treat-to-target strategy with adalimumab plus methotrexate versus placebo plus methotrexate: secondary analyses from the randomised controlled OPERA trial.'), 
	('Kristian Stengaard-Pedersen', 'Expression of soluble CD83 in plasma from early-stage rheumatoid arthritis patients is not modified by anti-TNF-α therapy.'), 
	('Ricardo M Xavier', 'Response to Comment on "The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis".'), 
	('Ricardo M Xavier', 'Subcutaneous Tocilizumab in Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Latin American Patients With Moderate to Severe Active Rheumatoid Arthritis: A Multicenter, Phase IIIb Study.'), 
	('Ricardo M Xavier', 'Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.'), 
	('Ricardo M Xavier', 'Prevalence of rheumatoid cachexia in rheumatoid arthritis: a systematic review and meta-analysis.'), 
	('Ricardo M Xavier', 'Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials.'), 
	('Ricardo M Xavier', 'The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis.'), 
	('Ricardo M Xavier', 'Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study.'), 
	('Stefan Florentinus', 'Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III Trial.'), 
	('Stefan Florentinus', 'Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis.'), 
	('Stefan Florentinus', 'Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate.'), 
	('Stefan Florentinus', 'Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis.'), 
	('Stefan Florentinus', 'Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.'), 
	('Stefan Florentinus', 'Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis.'), 
	('Stefan Florentinus', 'Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial.'), 
	('Stefan Florentinus', 'Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.'), 
	('Stefan Florentinus', 'Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis.'), 
	('Vivian P Bykerk', 'Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment.'), 
	('Vivian P Bykerk', 'On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.'), 
	('Vivian P Bykerk', 'Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis.'), 
	('Vivian P Bykerk', 'A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.'), 
	('Vivian P Bykerk', 'Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis.'), 
	('Vivian P Bykerk', 'Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.'), 
	('Vivian P Bykerk', 'Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.'), 
	('Vivian P Bykerk', 'Identification of Distinct Disease Activity Trajectories in Methotrexate-Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty-Four Months.'), 
	('Vivian P Bykerk', 'Can Patients With Controlled Rheumatoid Arthritis Taper Methotrexate From Targeted Therapy and Sustain Remission? A Systematic Review and Metaanalysis.'), 
	('Vivian P Bykerk', 'The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study.'), 
	('Benjamin Hsu', 'Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial.'), 
	('Benjamin Hsu', 'Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T).'), 
	('Benjamin Hsu', 'Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab.'), 
	('Benjamin Hsu', 'Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.'), 
	('Benjamin Hsu', 'Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients.'), 
	('Benjamin Hsu', 'Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE).'), 
	('Benjamin Hsu', 'Exposure-Response Modeling Analyses for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin 6, in Patients With Moderately to Severely Active Rheumatoid Arthritis.'), 
	('Benjamin Hsu', 'Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study.'), 
	('Benjamin Hsu', 'Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy.'), 
	('Benjamin Hsu', 'Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.'), 
	('Benjamin Hsu', 'Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients With Moderately to Severely Active Rheumatoid Arthritis.'), 
	('Benjamin Hsu', 'Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders.'), 
	('Georg Schett', 'Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study.'), 
	('Georg Schett', 'Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.'), 
	('Georg Schett', 'Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study.'), 
	('Georg Schett', 'Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.'), 
	('Georg Schett', 'Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.'), 
	('Atsushi Kawakami', 'Denosumab improves bone mineral density and microarchitecture in rheumatoid arthritis: randomized controlled trial by HR-pQCT.'), 
	('Atsushi Kawakami', 'Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.'), 
	('Atsushi Kawakami', 'Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.'), 
	('Atsushi Kawakami', 'Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis.'), 
	('Atsushi Kawakami', 'Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).'), 
	('Atsushi Kawakami', 'Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.'), 
	('Atsushi Kawakami', 'Increased Expression of the lncRNA NRON Along With NFATc1/PIM-1 in Labial Salivary Glands of Sjögren's Syndrome Patients.'), 
	('Atsushi Kawakami', 'Single-arm, open-label pilot intervention study to investigate an effect of oral 5-aminolevulinic acid plus sodium ferrous citrate on glucocorticoid reduction in patients with adult-onset Still disease: Study protocol for clinical trial (SPIRIT compliant).'), 
	('Daniel E Furst', 'Improved outcomes in rheumatoid arthritis with obesity after a weight loss intervention: randomized trial.'), 
	('Daniel E Furst', 'Discrepancy Between Multibiomarker Disease Activity and Clinical Disease Activity Scores in Patients With Persistently Active Rheumatoid Arthritis.'), 
	('Daniel E Furst', 'Modified intention-to-treat analysis did not bias trial results.'), 
	('Daniel E Furst', 'On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.'), 
	('Daniel E Furst', 'Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study.'), 
	('Daniel E Furst', 'A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.'), 
	('Daniel E Furst', 'Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis.'), 
	('Daniel E Furst', 'Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.'), 
	('Daniel E Furst', 'Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis.'), 
	('Daniel E Furst', 'Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials.'), 
	('Daniel E Furst', 'Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials.'), 
	('Daniel E Furst', 'Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years.'), 
	('Daniel E Furst', 'Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials.'), 
	('Daniel E Furst', 'Agreements and Discrepancies between FDA Reports and Journal Papers on Biologic Agents Approved for Rheumatoid Arthritis: A Meta-Research Project.'), 
	('Daniel E Furst', 'The Rate of Adherence to Antiarthritis Medications and Associated Factors among Patients with Rheumatoid Arthritis: A Systematic Literature Review and Metaanalysis.'), 
	('Daniel E Furst', 'Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab.'), 
	('Daniel E Furst', 'Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis.'), 
	('Daniel E Furst', 'Marine Oil Supplements for Arthritis Pain: A Systematic Review and Meta-Analysis of Randomized Trials.'), 
	('Daniel E Furst', 'Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.'), 
	('Alain Cantagrel', 'Infectious risk associated to orthopaedic surgery for rheumatoid arthritis patients treated by anti-TNFalpha.'), 
	('Alain Cantagrel', 'The effect of periodontal treatment on patients with rheumatoid arthritis: The ESPERA randomised controlled trial.'), 
	('Alain Cantagrel', 'Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis.'), 
	('Alain Cantagrel', 'Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis.'), 
	('Alain Cantagrel', 'Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.'), 
	('Alain Cantagrel', 'An e-health interactive self-assessment website (Sanoia<sup>®</sup>) in rheumatoid arthritis. A 12-month randomized controlled trial in 320 patients.'), 
	('Alain Cantagrel', 'Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).'), 
	('Alain Cantagrel', 'Anti-citrullinated peptides antibodies in systemic sclerosis: Meta-analysis of frequency and meaning.'), 
	('Koichi Amano', 'Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study.'), 
	('Koichi Amano', 'Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).'), 
	('Koichi Amano', 'Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).'), 
	('Koichi Amano', 'Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3).'), 
	('Koichi Amano', 'Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).'), 
	('Koichi Amano', 'Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).'), 
	('Koichi Amano', 'Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study.'), 
	('Koichi Amano', 'Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.'), 
	('Koichi Amano', 'Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.'), 
	('Koichi Amano', 'Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.'), 
	('Koichi Amano', 'Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results.'), 
	('Koichi Amano', 'Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).'), 
	('Koichi Amano', 'Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A <i>post hoc</i> analysis of the SURPRISE study.'), 
	('Vibeke Strand', 'Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.'), 
	('Vibeke Strand', 'Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.'), 
	('Vibeke Strand', 'Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.'), 
	('Vibeke Strand', 'Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.'), 
	('Vibeke Strand', 'Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).'), 
	('Vibeke Strand', 'Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.'), 
	('Vibeke Strand', 'Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).'), 
	('Vibeke Strand', 'Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial.'), 
	('Vibeke Strand', 'Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.'), 
	('Vibeke Strand', 'Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.'), 
	('Vibeke Strand', 'Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.'), 
	('Vibeke Strand', 'Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY.'), 
	('Vibeke Strand', 'Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.'), 
	('Vibeke Strand', 'Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.'), 
	('Vibeke Strand', 'Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.'), 
	('Vibeke Strand', 'High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab.'), 
	('Vibeke Strand', 'Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study.'), 
	('Vibeke Strand', 'Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials.'), 
	('Vibeke Strand', 'Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.'), 
	('Vibeke Strand', 'Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity.'), 
	('Vibeke Strand', 'Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.'), 
	('Vibeke Strand', 'Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial.'), 
	('Vibeke Strand', 'Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.'), 
	('Vibeke Strand', 'Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study.'), 
	('Vibeke Strand', 'Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.'), 
	('Vibeke Strand', 'Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.'), 
	('Vibeke Strand', 'Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.'), 
	('Vibeke Strand', 'Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination.'), 
	('Vibeke Strand', 'Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.'), 
	('Vibeke Strand', 'Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.'), 
	('Vibeke Strand', 'Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study.'), 
	('Vibeke Strand', 'Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.'), 
	('Jiri Vencovsky', 'The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial.'), 
	('Jiri Vencovsky', 'OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy.'), 
	('Jiri Vencovsky', 'Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.'), 
	('Jiri Vencovsky', 'Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.'), 
	('Jiri Vencovsky', 'A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.'), 
	('Jiri Vencovsky', 'A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.'), 
	('Ernest Choy', 'Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses.'), 
	('Ernest Choy', 'Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.'), 
	('Ernest Choy', 'Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs.'), 
	('Ernest Choy', 'Economic evaluation of a brief education, self-management and upper limb exercise training in people with rheumatoid arthritis (EXTRA) programme: a trial-based analysis.'), 
	('Ernest Choy', 'Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.'), 
	('Ernest Choy', 'Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries.'), 
	('Daniel Aletaha', 'Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials.'), 
	('Daniel Aletaha', 'Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients.'), 
	('Daniel Aletaha', 'Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials.'), 
	('Daniel Aletaha', 'Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.'), 
	('Daniel Aletaha', 'Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis.'), 
	('Daniel Aletaha', 'Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis.'), 
	('Daniel Aletaha', 'Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point.'), 
	('Daniel Aletaha', 'Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE).'), 
	('Daniel Aletaha', 'Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3.'), 
	('Daniel Aletaha', 'Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology.'), 
	('Daniel Aletaha', 'Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.'), 
	('Daniel Aletaha', 'Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.'), 
	('Daniel Aletaha', 'Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.'), 
	('Benjamin A Fisher', 'The impact of concomitant Sjögren's disease on rheumatoid arthritis disease activity: a systematic review and meta-analysis.'), 
	('Benjamin A Fisher', 'TNFα regulates cortisol metabolism in vivo in patients with inflammatory arthritis.'), 
	('Benjamin A Fisher', 'Decrease in articular hypoxia and synovial blood flow at early time points following infliximab and etanercept treatment in rheumatoid arthritis.'), 
	('Benjamin A Fisher', 'Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy.'), 
	('Benjamin A Fisher', 'Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.'), 
	('Benjamin A Fisher', 'A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjögren's syndrome.'), 
	('Jeffrey Kaine', 'The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy.'), 
	('Jeffrey Kaine', 'Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.'), 
	('Jeffrey Kaine', 'Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.'), 
	('Jeffrey Kaine', 'A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.'), 
	('Michael T Nurmohamed', 'Effect of TNF inhibitors on arterial stiffness and intima media thickness in rheumatoid arthritis: a systematic review and meta-analysis.'), 
	('Michael T Nurmohamed', 'Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.'), 
	('Michael T Nurmohamed', 'Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.'), 
	('Michael T Nurmohamed', 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial.'), 
	('Michael T Nurmohamed', 'Favourable effect of a 'second hit' after 13 weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trial.'), 
	('Michael T Nurmohamed', 'Effectiveness of electronic drug monitoring feedback to increase adherence in patients with RA initiating a biological DMARD: a randomised clinical trial.'), 
	('Michael T Nurmohamed', 'Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.'), 
	('Michael T Nurmohamed', 'Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay.'), 
	('Michael T Nurmohamed', 'Smartphone-Assisted Patient-Initiated Care Versus Usual Care in Patients With Rheumatoid Arthritis and Low Disease Activity: A Randomized Controlled Trial.'), 
	('Michael T Nurmohamed', 'Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials.'), 
	('Michael T Nurmohamed', 'Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate.'), 
	('Michael T Nurmohamed', 'A meta-analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis.'), 
	('Patrick Durez', 'Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.'), 
	('Patrick Durez', 'Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis.'), 
	('Patrick Durez', 'Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study.'), 
	('Patrick Durez', 'Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.'), 
	('Patrick Durez', 'Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND.'), 
	('Patrick Durez', 'Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.'), 
	('Patrick Durez', 'Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.'), 
	('Patrick Durez', 'Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis.'), 
	('Patrick Durez', 'Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.'), 
	('Patrick Durez', 'Efficacy of golimumab in Belgian patients with active rheumatoid arthritis despite treatment with non-biologic disease-modifying anti-rheumatic drugs: sub-analysis of the GO-MORE study.'), 
	('Patrick Durez', 'Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trial.'), 
	('Patrick Durez', 'Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials.'), 
	('Patrick Durez', 'Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis.'), 
	('Patrick Durez', 'Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.'), 
	('Patrick Durez', 'Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.'), 
	('Patrick Durez', 'Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomes.'), 
	('Patrick Durez', 'Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial.'), 
	('Patrick Durez', 'Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.'), 
	('Patrick Durez', 'Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.'), 
	('Iain B McInnes', 'Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).'), 
	('Iain B McInnes', 'Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).'), 
	('Iain B McInnes', 'Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.'), 
	('Iain B McInnes', 'Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.'), 
	('Iain B McInnes', 'Decrease in articular hypoxia and synovial blood flow at early time points following infliximab and etanercept treatment in rheumatoid arthritis.'), 
	('Iain B McInnes', 'Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis.'), 
	('Iain B McInnes', 'Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.'), 
	('Iain B McInnes', 'A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.'), 
	('Iain B McInnes', 'Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.'), 
	('Iain B McInnes', 'A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.'), 
	('Iain B McInnes', 'Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.'), 
	('Iain B McInnes', 'Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.'), 
	('Iain B McInnes', 'Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.'), 
	('Iain B McInnes', 'Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.'), 
	('David Gruben', 'The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials.'), 
	('David Gruben', 'Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.'), 
	('David Gruben', 'Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial.'), 
	('David Gruben', 'Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.'), 
	('David Gruben', 'Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.'), 
	('David Gruben', 'Tofacitinib versus methotrexate in rheumatoid arthritis.'), 
	('David Gruben', 'Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.'), 
	('David Gruben', 'Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis.'), 
	('David Gruben', 'Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.'), 
	('Dirkjan van Schaardenburg', 'Effectiveness of an integrated care intervention on supervisor support and work functioning of workers with rheumatoid arthritis.'), 
	('Dirkjan van Schaardenburg', 'Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?'), 
	('Dirkjan van Schaardenburg', 'Economic evaluation of an intervention program with the aim to improve at-work productivity for workers with rheumatoid arthritis.'), 
	('Dirkjan van Schaardenburg', 'An ultrasound negative for subclinical synovitis in arthralgia patients: is it helpful in identifying those not developing arthritis?'), 
	('Dirkjan van Schaardenburg', 'Effectiveness and cost-effectiveness of longstanding exercise therapy versus usual care in patients with axial spondyloarthritis or rheumatoid arthritis and severe limitations: The protocols of two parallel randomized controlled trials.'), 
	('Dirkjan van Schaardenburg', 'Favourable effect of a 'second hit' after 13 weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trial.'), 
	('Dirkjan van Schaardenburg', 'Effectiveness of longstanding exercise therapy compared with usual care for people with rheumatoid arthritis and severe functional limitations: a randomised controlled trial.'), 
	('Dirkjan van Schaardenburg', 'Smartphone-Assisted Patient-Initiated Care Versus Usual Care in Patients With Rheumatoid Arthritis and Low Disease Activity: A Randomized Controlled Trial.'), 
	('Dirkjan van Schaardenburg', 'A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks.'), 
	('Dirkjan van Schaardenburg', 'Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial.'), 
	('Dirkjan van Schaardenburg', 'Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial.'), 
	('Charles Peterfy', 'The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy.'), 
	('Charles Peterfy', 'Pre-treatment whole blood gene expression is associated with 14-week response assessed by dynamic contrast enhanced magnetic resonance imaging in infliximab-treated rheumatoid arthritis patients.'), 
	('Charles Peterfy', 'Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.'), 
	('Charles Peterfy', 'MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study.'), 
	('Charles Peterfy', 'Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis.'), 
	('Charles Peterfy', 'Magnetic resonance imaging of the hand and wrist in a randomized, double-blind, multicenter, placebo-controlled trial of infliximab for rheumatoid arthritis: Comparison of dynamic contrast enhanced assessments with semi-quantitative scoring.'), 
	('Charles Peterfy', 'Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.'), 
	('Charles Peterfy', 'Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy.'), 
	('Charles Peterfy', 'A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis.'), 
	('Charles Peterfy', 'MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.'), 
	('Charles Peterfy', 'Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial.'), 
	('Eric L Matteson', 'Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data.'), 
	('Eric L Matteson', 'Optimization of flare management in patients with rheumatoid arthritis: results of a randomized controlled trial.'), 
	('Eric L Matteson', 'Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study.'), 
	('Eric L Matteson', 'Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.'), 
	('Eric L Matteson', 'Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.'), 
	('Eric L Matteson', 'Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial.'), 
	('Eric L Matteson', 'Rate, risk factors and causes of mortality in patients with Sjögren's syndrome: a systematic review and meta-analysis of cohort studies.'), 
	('Eric L Matteson', 'Polymyalgia rheumatica and risk of coronary artery disease: a systematic review and meta-analysis of observational studies.'), 
	('Pit J S M Kerstens', 'Repair of joint damage in patients with rheumatoid arthritis does not relate to previous suppression of inflammation: a subanalysis after 8 years treat-to-target in the BeSt-trial.'), 
	('Pit J S M Kerstens', 'Continued participation in a ten-year tight control treat-to-target study in rheumatoid arthritis: why keep patients doing their best?'), 
	('Pit J S M Kerstens', 'Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis.'), 
	('Pit J S M Kerstens', 'Favourable effect of a 'second hit' after 13 weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trial.'), 
	('Pit J S M Kerstens', 'Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.'), 
	('Pit J S M Kerstens', 'Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?'), 
	('Naoki Ishiguro', 'Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.'), 
	('Naoki Ishiguro', 'Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies.'), 
	('Naoki Ishiguro', 'Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study.'), 
	('Naoki Ishiguro', 'Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis.'), 
	('Naoki Ishiguro', 'Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial.'), 
	('Naoki Ishiguro', 'Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial.'), 
	('Naoki Ishiguro', 'The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.'), 
	('Naoki Ishiguro', 'Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study.'), 
	('Naoki Ishiguro', 'Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis.'), 
	('Naoki Ishiguro', 'Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).'), 
	('Naoki Ishiguro', 'Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3).'), 
	('Naoki Ishiguro', 'Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).'), 
	('Naoki Ishiguro', 'Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).'), 
	('Naoki Ishiguro', 'Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.'), 
	('Naoki Ishiguro', 'Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies.'), 
	('Naoki Ishiguro', 'Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.'), 
	('Naoki Ishiguro', 'Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.'), 
	('Naoki Ishiguro', 'Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients.'), 
	('Naoki Ishiguro', 'Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.'), 
	('Naoki Ishiguro', 'Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis.'), 
	('Naoki Ishiguro', 'Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120.'), 
	('Naoki Ishiguro', 'Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results.'), 
	('Naoki Ishiguro', 'Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.'), 
	('Naoki Ishiguro', 'Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.'), 
	('Jacob M van Laar', 'Explorative analyses of protein biomarkers in patients with early rheumatoid arthritis achieving sustained drug-free remission after treatment with tocilizumab- or methotrexate-based strategies: from transcriptomics to proteomics.'), 
	('Jacob M van Laar', 'Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies.'), 
	('Jacob M van Laar', 'Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.'), 
	('Jacob M van Laar', 'Current Smoking Negatively Affects the Response to Methotrexate in Rheumatoid Arthritis in a Dose-responsive Way, Independently of Concomitant Prednisone Use.'), 
	('Jacob M van Laar', 'Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy.'), 
	('Jacob M van Laar', 'Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.'), 
	('Jacob M van Laar', 'Intravenous pegylated liposomal prednisolone outperforms intramuscular methylprednisolone in treating rheumatoid arthritis flares: A randomized controlled clinical trial.'), 
	('Jacob M van Laar', 'Automated joint space width quantification of hand and wrist joints: a proof of concept study.'), 
	('Jacob M van Laar', 'Glucocorticoids in early rheumatoid arthritis: are the benefits of joint-sparing effects offset by the adverse effect of osteoporosis? the effects on bone in the utrecht study and the CAMERA-II study.'), 
	('Jacob M van Laar', 'Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.'), 
	('Jacob M van Laar', 'AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa, randomized, double-blind, efficacy, and safety study.'), 
	('Elizabeth C Hsia', 'Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial.'), 
	('Elizabeth C Hsia', 'Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.'), 
	('Elizabeth C Hsia', 'Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age.'), 
	('Elizabeth C Hsia', 'Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis.'), 
	('Elizabeth C Hsia', 'Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.'), 
	('Elizabeth C Hsia', 'Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.'), 
	('Rieke Alten', 'Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy.'), 
	('Rieke Alten', 'Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.'), 
	('Rieke Alten', 'Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.'), 
	('Rieke Alten', 'Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis.'), 
	('Rieke Alten', 'Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications.'), 
	('Rieke Alten', 'Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies.'), 
	('Rieke Alten', 'Improvement Thresholds for Morning Stiffness Duration in Patients Receiving Delayed- Versus Immediate-Release Prednisone for Rheumatoid Arthritis.'), 
	('Rieke Alten', 'Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis.'), 
	('Rieke Alten', 'Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54.'), 
	('Rieke Alten', 'Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis.'), 
	('Rieke Alten', 'Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study.'), 
	('Rieke Alten', 'Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.'), 
	('Rieke Alten', 'Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept.'), 
	('Rieke Alten', 'A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.'), 
	('Rieke Alten', 'Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials.'), 
	('Rieke Alten', 'Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293.'), 
	('Rieke Alten', 'Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis.'), 
	('Rieke Alten', 'A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.'), 
	('Rieke Alten', 'Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.'), 
	('Rieke Alten', 'Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study).'), 
	('Hartmut Kupper', 'Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III Trial.'), 
	('Hartmut Kupper', 'Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA Trial.'), 
	('Hartmut Kupper', 'Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate.'), 
	('Hartmut Kupper', 'Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial.'), 
	('Hartmut Kupper', 'Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.'), 
	('Hartmut Kupper', 'Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.'), 
	('Johannes W G Jacobs', 'Remission definitions guiding immunosuppressive therapy in rheumatoid arthritis: which is best fitted for the purpose?'), 
	('Johannes W G Jacobs', 'Contribution of the subjective components of the disease activity score to the response to biologic treatment in rheumatoid arthritis.'), 
	('Johannes W G Jacobs', 'Explorative analyses of protein biomarkers in patients with early rheumatoid arthritis achieving sustained drug-free remission after treatment with tocilizumab- or methotrexate-based strategies: from transcriptomics to proteomics.'), 
	('Johannes W G Jacobs', 'Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients.'), 
	('Johannes W G Jacobs', 'Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies.'), 
	('Johannes W G Jacobs', 'Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.'), 
	('Johannes W G Jacobs', 'A disconnect between disease activity and functional ability already in patients with early rheumatoid arthritis, depending on large joint involvement.'), 
	('Johannes W G Jacobs', 'Current Smoking Negatively Affects the Response to Methotrexate in Rheumatoid Arthritis in a Dose-responsive Way, Independently of Concomitant Prednisone Use.'), 
	('Johannes W G Jacobs', 'Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy.'), 
	('Johannes W G Jacobs', 'The impact of patient global assessment in the definition of remission as a predictor of long-term radiographic damage in patients with rheumatoid arthritis: protocol for an individual patient data meta-analysis.'), 
	('Johannes W G Jacobs', 'Alternative Ways to Quantify Sustained Remission: Applying the Continuity Rewarded Score and Patient Vector Graph.'), 
	('Johannes W G Jacobs', 'Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology.'), 
	('Johannes W G Jacobs', 'Is radiographic progression a downside of stopping TNF-inhibitor in RA patients with low disease activity, if this is followed by flare? A sub-study of the POET-US trial.'), 
	('Johannes W G Jacobs', 'Automated joint space width quantification of hand and wrist joints: a proof of concept study.'), 
	('Johannes W G Jacobs', 'Glucocorticoids in early rheumatoid arthritis: are the benefits of joint-sparing effects offset by the adverse effect of osteoporosis? the effects on bone in the utrecht study and the CAMERA-II study.'), 
	('Johannes W G Jacobs', 'Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab.'), 
	('Johannes W G Jacobs', 'Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors.'), 
	('Jonathan Kay', 'Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.'), 
	('Jonathan Kay', 'Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.'), 
	('Jonathan Kay', 'Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study.'), 
	('Jonathan Kay', 'Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.'), 
	('Jonathan Kay', 'Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.'), 
	('Jonathan Kay', 'Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study.'), 
	('Jonathan Kay', 'Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.'), 
	('Jonathan Kay', 'Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.'), 
	('Su Chen', 'Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis.'), 
	('Su Chen', 'Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate.'), 
	('Su Chen', 'Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis.'), 
	('Su Chen', 'Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial.'), 
	('Su Chen', 'Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study.'), 
	('Su Chen', 'Efficacy and Safety of ABBV-3373, a Novel Anti-Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody-Drug Conjugate, in Adults with Moderate-to-Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double-Blind, Active-Controlled Proof-of-Concept Phase IIa Trial.'), 
	('Su Chen', 'Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis.'), 
	('Adeline Ruyssen-Witrand', 'Infectious risk associated to orthopaedic surgery for rheumatoid arthritis patients treated by anti-TNFalpha.'), 
	('Adeline Ruyssen-Witrand', 'Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients.'), 
	('Adeline Ruyssen-Witrand', 'Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis.'), 
	('Adeline Ruyssen-Witrand', 'Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis.'), 
	('Adeline Ruyssen-Witrand', 'Influence of perceived barriers and facilitators for physical activity on physical activity levels in patients with rheumatoid arthritis or spondyloarthritis: a cross-sectional study of 150 patients.'), 
	('Adeline Ruyssen-Witrand', 'A single nucleotide polymorphism of IL6-receptor is associated with response to tocilizumab in rheumatoid arthritis patients.'), 
	('Adeline Ruyssen-Witrand', 'Is self-assessment by patients of disease activity acceptable over the long term in rheumatoid arthritis? A 3-year follow-up of 771 patients.'), 
	('Adeline Ruyssen-Witrand', 'Anti-citrullinated peptides antibodies in systemic sclerosis: Meta-analysis of frequency and meaning.'), 
	('Maarten Boers', 'Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis.'), 
	('Maarten Boers', 'Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?'), 
	('Maarten Boers', 'A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3×3 Methodology Applied to Two Active Comparator Trials.'), 
	('Maarten Boers', 'Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials.'), 
	('Maarten Boers', 'Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?'), 
	('Maarten Boers', 'Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial.'), 
	('Maarten Boers', 'The short-term effects of two high-dose, step-down prednisolone regimens on body composition in early rheumatoid arthritis.'), 
	('Maarten Boers', 'Glucocorticoid-trials in rheumatoid arthritis mostly study representative real-world patients: A systematic review and meta-analysis.'), 
	('Maarten Boers', 'Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up.'), 
	('Maarten Boers', 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial.'), 
	('Maarten Boers', 'Alternative Ways to Quantify Sustained Remission: Applying the Continuity Rewarded Score and Patient Vector Graph.'), 
	('Maarten Boers', 'Effective Treatment for Rapid Improvement of Both Disease Activity and Self-Reported Physical Activity in Early Rheumatoid Arthritis.'), 
	('Maarten Boers', 'Further Simplification of the Simple Erosion Narrowing Score With Item Response Theory Methodology.'), 
	('Maarten Boers', 'Association Between Participant Retention and the Proportion of Included Elderly People in Rheumatology Trials: Results From a Series of Exploratory Meta-Regression Analyses.'), 
	('Maarten Boers', 'Applicability of trials in rheumatoid arthritis and osteoarthritis: A systematic review and meta-analysis of trial populations showing adequate proportion of women, but underrepresentation of elderly people.'), 
	('Maarten Boers', 'Initial high-dose prednisolone combination therapy using COBRA and COBRA-light in early rheumatoid arthritis.'), 
	('Maarten Boers', 'Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.'), 
	('Maarten Boers', 'Smartphone-Assisted Patient-Initiated Care Versus Usual Care in Patients With Rheumatoid Arthritis and Low Disease Activity: A Randomized Controlled Trial.'), 
	('Maarten Boers', 'A multidisciplinary lifestyle program for rheumatoid arthritis: the 'Plants for Joints' randomized controlled trial.'), 
	('Maarten Boers', 'A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks.'), 
	('Maarten Boers', 'Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.'), 
	('Maarten Boers', 'Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.'), 
	('Maarten Boers', 'Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial.'), 
	('Maarten Boers', 'Balneotherapy (or spa therapy) for rheumatoid arthritis.'), 
	('Maarten Boers', 'Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis.'), 
	('Laure Gossec', 'Impact of comorbidities on fatigue in rheumatoid arthritis patients: Results from a nurse-led program for comorbidities management (COMEDRA).'), 
	('Laure Gossec', 'Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis.'), 
	('Laure Gossec', 'Screening for and management of comorbidities after a nurse-led program: results of a 3-year longitudinal study in 769 established rheumatoid arthritis patients.'), 
	('Laure Gossec', 'Remission definitions guiding immunosuppressive therapy in rheumatoid arthritis: which is best fitted for the purpose?'), 
	('Laure Gossec', 'Psychometric properties of sleep and coping numeric rating scales in rheumatoid arthritis: a subanalysis of an etanercept trial.'), 
	('Laure Gossec', 'A randomized controlled trial for improving patient self-assessment of synovitis in rheumatoid arthritis with education by ultrasonography: the RAEUS Study.'), 
	('Laure Gossec', 'Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients.'), 
	('Laure Gossec', 'Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA).'), 
	('Laure Gossec', 'Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.'), 
	('Laure Gossec', 'The impact of patient global assessment in the definition of remission as a predictor of long-term radiographic damage in patients with rheumatoid arthritis: protocol for an individual patient data meta-analysis.'), 
	('Laure Gossec', 'Patient-perceived flares in rheumatoid arthritis: A sub-analysis of the STRASS treatment tapering strategy trial.'), 
	('Laure Gossec', 'Patient-Physician Discordance in Global Assessment in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis.'), 
	('Laure Gossec', 'Improvement in patient-reported outcomes after rituximab in rheumatoid arthritis patients: An open-label assessment of 175 patients.'), 
	('Laure Gossec', 'Evaluation of the Implementation of Guidelines on the Treatment of Osteoporosis in Patients with Rheumatoid Arthritis.'), 
	('Laure Gossec', 'An e-health interactive self-assessment website (Sanoia<sup>®</sup>) in rheumatoid arthritis. A 12-month randomized controlled trial in 320 patients.'), 
	('Laure Gossec', 'Is self-assessment by patients of disease activity acceptable over the long term in rheumatoid arthritis? A 3-year follow-up of 771 patients.'), 
	('Laure Gossec', 'Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.'), 
	('Samuel H Zwillich', 'Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6.'), 
	('Samuel H Zwillich', 'Meta-analysis of long-term joint structural deterioration in minimally treated patients with rheumatoid arthritis.'), 
	('Samuel H Zwillich', 'Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.'), 
	('Samuel H Zwillich', 'Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial.'), 
	('Samuel H Zwillich', 'Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.'), 
	('Samuel H Zwillich', 'Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.'), 
	('Samuel H Zwillich', 'Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.'), 
	('Samuel H Zwillich', 'Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis.'), 
	('Samuel H Zwillich', 'Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers.'), 
	('Joshua F Baker', 'Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept.'), 
	('Joshua F Baker', 'Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis.'), 
	('Joshua F Baker', 'Relationship of patient-reported outcomes with MRI measures in rheumatoid arthritis.'), 
	('Joshua F Baker', 'Determining MRI Inflammation Targets When Considering a Rheumatoid Arthritis Treat-to-Target Strategy: Results of a Randomized, Placebo-Controlled Trial.'), 
	('Joshua F Baker', 'Greater body mass independently predicts less radiographic progression on X-ray and MRI over 1-2 years.'), 
	('Joshua F Baker', 'Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial.'), 
	('Joshua F Baker', 'Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis.'), 
	('Joshua F Baker', 'Magnetic resonance imaging assessed inflammation in the wrist is associated with patient-reported physical impairment, global assessment of disease activity and pain in early rheumatoid arthritis: longitudinal results from two randomised controlled trials.');
